î Vistagen Therapeutics Incã®çŸåšã®è²¡åã¹ã³ã¢ã¯7.38ã§ãã ãã®è²¡åç¶æ³ã¯å
調ã§ãã ãŸããäºæ¥å¹çã¯äœãã§ãã ææ°ååæã®å£²äžé«ã¯1.48Mã§ãåå¹Žåææ¯å¢å ã®504.92%ã§ãããäžæ¹ãçŽå©çã¯åå¹Žåææ¯å¢å ã®13.68%ãšãªããŸããã
î Vistagen Therapeutics Incã®çŸåšã®ããªã¥ãšãŒã·ã§ã³ã¹ã³ã¢ã¯8.90ã§ãã çŸåšã®PERã¯-0.10ã§ãçŽè¿é«å€-0.01ã-93.11%äžåããçŽè¿å®å€-4.33ã-4422.03%äžåã£ãŠããŸãã
î Vistagen Therapeutics Incã®çŸåšã®åçäºæž¬ã¹ã³ã¢ã¯6.00ã§ãã ç®æšæ ªäŸ¡ã®å¹³åã¯0.97ã§ãæé«ã¯1.00ãæäœã¯0.90ã§ãã
î Vistagen Therapeutics Incã®çŸåšã®äŸ¡æ Œã¢ã¡ã³ã¿ã ã¹ã³ã¢ã¯4.49ã§ãã çŸåšãæ ªäŸ¡ã¯æµæç·0.21ãšæ¯æç·0.16ã®éã§æšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
î Vistagen Therapeutics Incã®çŸåšã®æ©é¢æè³å®¶ææ ªã¹ã³ã¢ã¯3.00ã§ãã ææ°ã®æ©é¢æè³å®¶ä¿ææ¯çã¯37.96%ã§ãåååææ¯æžå°34.37%ã§ãã
î Vistagen Therapeutics Incã®çŸåšã®ãªã¹ã¯è©äŸ¡ã¹ã³ã¢ã¯1.56ã§ãã å瀟ã®ããŒã¿å€ã¯0.31ã§ãã ããã¯ãäžæçžå Žã§ã¯æ ªäŸ¡ãåžå Žå
šäœïŒææ°ïŒãäžåãåŸåãããäžæ¹ã§ãäžèœçžå Žã§ã¯äžèœå¹
ãéå®çãšãªãåŸåã瀺ããŠããŸãã